NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis $1.33 -0.01 (-0.75%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.38%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About MediciNova Stock (NASDAQ:MNOV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MediciNova alerts:Sign Up Key Stats Today's Range$1.26▼$1.4150-Day Range$1.33▼$3.4552-Week Range$1.22▼$3.90Volume115,567 shsAverage Volume49,955 shsMarket Capitalization$68.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingModerate Buy Company Overview MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines. MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.AI Generated. May Contain Errors. Read More MediciNova Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreMNOV MarketRank™: 2.9483015293 of 5 starsMediciNova scored higher than 59% of companies evaluated by MarketBeat, and ranked 753rd out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMediciNova has a consensus price target of $7.75, representing about 482.7% upside from its current price of $1.33.Amount of Analyst CoverageMediciNova has only been the subject of 3 research reports in the past 90 days.Read more about MediciNova's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.25) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediciNova is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediciNova is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.67% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 5.44.Change versus previous monthShort interest in MediciNova has recently decreased by 2.44%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.07 News SentimentMediciNova has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for MediciNova this week, compared to 2 articles on an average week. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,000.00 in company stock.Percentage Held by Insiders14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions9.90% of the stock of MediciNova is held by institutions.Read more about MediciNova's insider trading history. Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNOV Stock News HeadlinesMedicinova IncNovember 14, 2026 | money.usnews.comMediciNova to Participate in the Maxim Growth SummitOctober 6, 2026 | globenewswire.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 18 at 1:00 AM | Porter & Company (Ad)MediciNova stock tumbles on mixed Phase 2 NAFLD trial dataSeptember 28, 2026 | finance.yahoo.comMediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary EndpointsSeptember 28, 2026 | finance.yahoo.comMediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In PremarketSeptember 28, 2026 | rttnews.comMediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)September 28, 2026 | globenewswire.comMNOV Stock In Focus As COMBAT-ALS Completes Double-Blind Phase; Results Due By Year-EndSeptember 24, 2026 | rttnews.comSee More Headlines MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed this year? MediciNova's stock was trading at $1.31 at the beginning of the year. Since then, MNOV stock has increased by 1.5% and is now trading at $1.33. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.00. The biopharmaceutical company had revenue of $138.56 thousand for the quarter, compared to the consensus estimate of $50 thousand. MediciNova had a negative net margin of 1,126.60% and a negative trailing twelve-month return on equity of 26.47%. Who are MediciNova's major shareholders? MediciNova's top institutional investors include Goldman Sachs Group Inc. (1.25%), State Street Corp (0.39%), Empowered Funds LLC (0.10%) and Jump Financial LLC (0.04%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include NVIDIA (NVDA), Nokia (NOK), Ideanomics (IDEX), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), Ford Motor (F) and GE Aerospace (GE). Company Calendar Last Earnings11/12/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MNOV's financial health is in the Red zone, according to TradeSmith. MNOV has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MNOV CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees6Year Founded2000Price Target and Rating Average Price Target for MediciNova$7.75 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+482.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12 million Net Margins-1,126.60% Pretax Margin-1,126.07% Return on Equity-26.47% Return on Assets-24.24% Debt Debt-to-Equity RatioN/A Current Ratio8.75 Quick Ratio8.75 Sales & Book Value Annual Sales$410 thousand Price / Sales166.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.66Miscellaneous Outstanding Shares51,230,000Free Float44,060,000Market Cap$68.14 million OptionableOptionable Beta0.71 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:MNOV) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.